Welcome to the Department of Radiation Oncology

Message from James M. Metz, MD — Chairman

Penn Radiation Oncology is dedicated to a three-part mission of excellence in patient care, basic and translational research, and the education of residents and students. We are committed to delivering excellence in every area and as such we steadfastly believe that "Excellence is Standard."

Penn Radiation Oncology is one of the most comprehensive radiation oncology programs in the world. The outstanding faculty and staff, combined with Penn’s extensive collection of advanced technology, gives patients access to nearly every treatment option available for their cancer. The broad range of radiation treatments available include proton therapy, intensity-modulated radiation therapy (IMRT), high-dose rate (HDR) and low-dose rate brachytherapy, partial breast irradiation, stereotactic radiosurgery (SRS), and Gamma Knife radiation. With the Abramson Cancer Center of the University of Pennsylvania, Penn Radiation Oncology provides patient care at the Ruth and Raymond Perelman Center for Advanced Medicine and seven community-based sites.

Read more of the Message from the Chair »

News

  • NEJM Study on Four Decades of U.S. Medical Faculty Diversity Thursday, April 14, 2022

    Data in the New England Journal of Medicine points to an urgent need to achieve workforce diversity in academic medicine. The study’s author, Neha Vapiwala, MD, a professor of Radiation Oncology, conveyed the importance of addressing imbalances in representation to support all populations served, and that academic medical institutions must foster an inclusive environment and focus on retention and promotion of individuals from underrepresented communities.

  • Penn Medicine Awarded $12.3M NIH Grant to Study Ultra-Fast, High-Dose FLASH Radiation Therapy for Cancer Tuesday, March 1, 2022

    With more than $12 million in new funding from the National Institutes of Health (NIH), the Abramson Cancer Center at the University of Pennsylvania will build on its preclinical research of an emerging form of radiation that provides ultra-fast doses—of under a second, compared to several minutes with conventional radiation—and shows promise of greater protection of normal tissue, thereby minimizing toxic effects to the body.

  • Scientists Study Microbiome’s Role in CAR-T Outcomes in Cancer Patients Monday, January 10, 2022

    As cancer-killing CAR-T cells course through the body, they make occasional pit stops at the gut. What they do there — and which gut microbes they meet up with — could potentially change the prospects of these engineered immune cells. Andrea Facciabene, PhD, a research associate professor of Radiation Oncology and Obstetrics/Gynecology, presented data during ASH 2021 on gut microbiota tuning in lymphoma. Preclinical research including murine-model work evaluated the potential benefit of gut microbiota tuning in patients with acute lymphoid leukemia and non-Hodgkin’s lymphoma.

More News

Upcoming Events

    More Events